文献速递MDS 与骨髓增殖性肿瘤

迈向真性红细胞增多症的疾病修饰治疗

Moving toward disease modification in polycythemia vera.
PubMed 文献 · Blood · 2023-01-01

真性红细胞增多症(PV)以JAK2激活突变为特征,表现为红细胞增多、全身及血管舒缩症状,并增加血栓栓塞及向骨髓纤维化和急性髓系白血病(AML)进展的风险。治疗选择基于年龄和血栓史:低危患者单用治疗性放血和 aspirin,高危患者加用羟基脲或干扰素α(IFN-α)等细胞减灭治疗。近期研究显示 ropegylated IFN-α2b 安全有效,支持用于低危PV患者;早期治疗与更高分子学缓解率相关,可能实现限时治疗,但需更长随访评估分子学缓解与临床结局的关联。

要点

  • 低危PV患者单用治疗性放血和aspirin,高危患者加用羟基脲或IFN-α等细胞减灭治疗。
  • 显著疾病相关症状、脾大、并发血小板增多和白细胞增多或放血不耐受,可构成低危患者细胞减灭治疗指征。
  • ropegylated IFN-α2b 研究显示安全有效,支持用于低危PV患者;早期治疗与更高分子学缓解率相关,可能实现限时治疗。

核心结论

  • 本文概述PV当前和演变中的治疗格局,并提出以患者为中心、免放血、早期使用限时疾病修饰治疗模式的愿景,该模式可能最终影响疾病自然史。

研究设计与样本

  • 综述:概述PV当前和演变中的治疗格局,并勾勒作者对以患者为中心、免放血、早期限时疾病修饰治疗的愿景。

主要发现

  • PV属于BCR-ABL1阴性骨髓增殖性肿瘤,以JAK2激活突变为特征,临床表现为红细胞增多、不同程度的全身和血管舒缩症状,以及血栓栓塞事件和向骨髓纤维化及急性髓系白血病(AML)进展的风险增加。
  • 治疗选择基于患者年龄和血栓史:低危PV患者单用治疗性放血和aspirin,高危患者加用羟基脲或干扰素α(IFN-α)等细胞减灭治疗。
  • 显著疾病相关症状和脾大、并发血小板增多和白细胞增多或放血不耐受,可构成其他方面低危患者细胞减灭治疗的指征。
  • 近期研究显示ropegylated IFN-α2b安全有效(即减少放血需求和分子学缓解),支持其用于低危PV患者。
  • 新出现的数据提示早期治疗与更高分子学缓解率相关,可能最终实现限时治疗;但需更长随访评估分子学缓解是否与血栓形成及向骨髓纤维化或AML进展等临床有意义结局相关。

临床怎么用

  • 作者提出以患者为中心、免放血、早期使用限时疾病修饰治疗模式的愿景,该模式可能最终影响疾病自然史。

局限性

  • 需更长随访评估分子学缓解是否与血栓形成及向骨髓纤维化或AML进展等临床有意义结局相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Polycythemia vera (PV) belongs to the BCR-ABL1-negative myeloproliferative neoplasms and is characterized by activating mutations in JAK2 and clinically presents with erythrocytosis, variable degrees of systemic and vasomotor symptoms, and an increased risk of both thromboembolic events and progression to myelofibrosis and acute myeloid leukemia (AML). Treatment selection is based on a patient's age and a history of thrombosis in patients with low-risk PV treated with therapeutic phlebotomy and aspirin alone, whereas cytoreductive therapy with either hydroxyurea or interferon alfa (IFN-α) is added for high-risk disease. However, other disease features such as significant disease-related symptoms and splenomegaly, concurrent thrombocytosis and leukocytosis, or intolerance of phlebotomy can constitute an indication for cytoreductive therapy in patients with otherwise low-risk disease. Additionally, recent studies demonstrating the safety and efficacy (ie, reduction in phlebotomy requirements and molecular responses) of ropegylated IFN-α2b support its use for patients with low-risk PV. Additionally, emerging data suggest that early treatment is associated with higher rates of molecular responses, which might eventually enable time-limited therapy. Nonetheless, longer follow-up is needed to assess whether molecular responses associate with clinically meaningful outcome measures such as thrombosis and progression to myelofibrosis or AML. In this article, we provide an overview of the current and evolving treatment landscape of PV and outline our vision for a patient-centered, phlebotomy-free, treatment approach using time-limited, disease-modifying treatment modalities early in the disease course, which could ultimately affect the natural history of the disease.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Bewersdorf JP, How J, Masarova L, et al. Moving toward disease modification in polycythemia vera. Blood. 2023. PMID: 37729609. doi:10.1182/blood.2023021503

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。